EA201891731A1 - Оптимизированные гены фактора viii - Google Patents

Оптимизированные гены фактора viii

Info

Publication number
EA201891731A1
EA201891731A1 EA201891731A EA201891731A EA201891731A1 EA 201891731 A1 EA201891731 A1 EA 201891731A1 EA 201891731 A EA201891731 A EA 201891731A EA 201891731 A EA201891731 A EA 201891731A EA 201891731 A1 EA201891731 A1 EA 201891731A1
Authority
EA
Eurasian Patent Office
Prior art keywords
factor viii
codon
optimized
optimized sequences
optimized factor
Prior art date
Application number
EA201891731A
Other languages
English (en)
Inventor
Слюан Тан
Тонгао Лиу
Original Assignee
Биовератив Терапьютикс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Биовератив Терапьютикс Инк. filed Critical Биовератив Терапьютикс Инк.
Priority claimed from PCT/US2017/015879 external-priority patent/WO2017136358A1/en
Publication of EA201891731A1 publication Critical patent/EA201891731A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Согласно настоящему изобретению предложены кодон-оптимизированные последовательности фактора VIII, векторы и клетки-хозяева, содержащие кодон-оптимизированные последовательности фактора VIII, полипептиды, кодируемые кодон-оптимизированными последовательностями фактора VIII, и способы получения таких полипептидов. Согласно настоящему изобретению также предложены способы лечения расстройств системы свертывания крови, таких как гемофилия, включающие введение субъекту кодон-оптимизированной последовательности нуклеиновой кислоты фактора VIII или кодируемого указанной последовательностью полипептида.
EA201891731A 2016-10-18 2017-01-31 Оптимизированные гены фактора viii EA201891731A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662409739P 2016-10-18 2016-10-18
PCT/US2017/015879 WO2017136358A1 (en) 2016-02-01 2017-01-31 Optimized factor viii genes

Publications (1)

Publication Number Publication Date
EA201891731A1 true EA201891731A1 (ru) 2019-04-30

Family

ID=66436966

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891731A EA201891731A1 (ru) 2016-10-18 2017-01-31 Оптимизированные гены фактора viii

Country Status (1)

Country Link
EA (1) EA201891731A1 (ru)

Similar Documents

Publication Publication Date Title
PH12018501628A1 (en) Optimized factor viii genes
PH12019500694A1 (en) Factor viii compositions and methods of making and using the same
EP4223772A3 (en) Optimized factor viii gene
EA201890640A1 (ru) Рекомбинантные векторы, содержащие пептид 2а
EA201891092A1 (ru) Способы и композиции для редактирования генов в гемопоэтических стволовых клетках
SA518400424B1 (ar) جزيئات الجسم المضاد لعلاج السرطان
PH12018502361A1 (en) Gdf15 fusion proteins and uses thereof
EA202091710A1 (ru) Антитела против cd73 и способы их применения
MX2021006615A (es) Proteinas de union triespecificas y metodos de uso.
EA201990715A1 (ru) Стабилизирующие тример мутации белка оболочки hiv
WO2017011773A3 (en) Codon-optimized nucleic acids encoding antibodies
MX2015014464A (es) Vectores para terapia genica para tratar cardiomiopatía.
WO2017077329A3 (en) Nucleic acids, peptides and methods
PH12019500122A1 (en) Bispecific antibody-like binding proteins specifically binding to cd3 and cd123
EA201691576A1 (ru) Слитые белки, содержащие интерлейкин-2, и их применения
AU2015286820A8 (en) Stabilization of poly(A) sequence encoding DNA sequences
MX2019015502A (es) L-asparaginasa modificada.
BR112019004711A2 (pt) receptores de antígeno quiméricos compreendendo domínios de fibronectina tipo iii específicos para bcma e usos dos mesmos
NZ752941A (en) Frataxin expression constructs
EA201890351A1 (ru) Рекомбинантный orf-вирусный вектор
EA201891731A1 (ru) Оптимизированные гены фактора viii
EA201790362A1 (ru) Солюбилизированный фермент и его применения
NZ774631A (en) Composition for preventing or treating benign tumor
PH12019502442A1 (en) Variants of human bmp7 protein
EA201991181A1 (ru) Psma-нацеленные триспецифические белки и способы их применения